Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Open-Label IV Abatacept in Japanese Children and Adolescents With Active Juvenile Idiopathic Arthritis
jRCT2080222073Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of abatacept in juvenile idiopathic arthritis (JIA), sponsored by Bristol Myers Squibb. Started May 2013; status: completed.
02
Drugs
abatacept
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on jRCT2080222073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222073.